{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:38Z","timestamp":1777934618320,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chemotherapy-induced nausea and vomiting (CINV) is one of the adverse events that most affects oncologic patients\u2019 quality of life. Carboplatin AUC\u2009\u2265\u20094 belongs to agents with high emetic risk (moderate risk in ASCO guidelines). We aimed to compare the effectiveness of netupitant\/palonosetron and dexamethasone triple combination (TC) therapy versus ondansetron and dexamethasone double combination (DC) therapy as antiemetic prophylaxis in patients with carboplatin AUC\u2009\u2265\u20094. As a secondary endpoint, in TC group we evaluated the effectiveness of changing NEPA administration timing from 1\u2005h to 15\u2005min before chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Open-label prospective study conducted in a tertiary-care hospital in patients receiving carboplatin AUC\u2009\u2265\u20094. CINV was evaluated using MASCC antiemetic tool, in acute (&lt;24\u2005h) and delayed phase (24\u2013120\u2005h). Results were analyzed using \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two-hundred four completed questionnaires (CQ) were analyzed (76 in DC and 128 in TC). The proportion of patients who remained emesis-free was superior for TC-treated group compared to DC, either in acute (99.2% vs 92.1%, p\u2009=\u20090.0115) and delayed phase (97.6% vs 90.7%, p\u2009=\u20090.043). Likewise, a higher proportion of TC-treated patients compared to DC remained nausea-free for the first 24\u2005h after treatment (90.6% vs 71%, p\u2009=\u20090.0004) and between 24 and 120\u2005h (82.3% vs 62.7%, p\u2009=\u20090.0025). The change of NEPA administration time showed similar effectiveness in terms of CINV control (81.6% vs 74.5%, p\u2009=\u20090.70).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TC showed superiority in early and delayed CINV control in carboplatin AUC\u2009\u2265\u20094 regimens, with no significant differences among cancer types. Change in NEPA administration timing has beneficial implications; it allows NEPA to be administered at hospitals before chemotherapy session.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231194077","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T02:40:51Z","timestamp":1691721651000},"page":"999-1009","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapy"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3223-670X","authenticated-orcid":false,"given":"Marta","family":"Albanell-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngela","family":"P\u00e9rez S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Monge-Escart\u00edn","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8259-0811","authenticated-orcid":false,"given":"Gisela","family":"Riu-Viladoms","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Carmen","family":"Rodr\u00edguez Mues","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Lourdes","family":"Corominas Bosch","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Gaba Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neus Bast\u00e9","family":"Roll\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed","family":"Reguart","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Soy Muner","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Barcelona, Spain"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain"},{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, School of Pharmacy, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Carcelero San Mart\u00edn","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Division of Medicines, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"bibr1-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0173-z"},{"key":"bibr2-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2009.11.001"},{"key":"bibr3-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6807"},{"key":"bibr4-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1073-9"},{"key":"bibr5-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"bibr6-10781552231194077","volume":"2","author":"Phillips RS","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr7-10781552231194077","first-page":"175","volume":"7","author":"Palli SR","year":"2015","journal-title":"Cancer Manag Res"},{"key":"bibr8-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj078"},{"key":"bibr9-10781552231194077","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 1. 2023. Antiemesis. [Internet]. 2023 [cited 2021 Apr 13]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"bibr10-10781552231194077","unstructured":"MASCC \/ ESMO Antiemetic Guideline 2016 with Updates in 2019. Multinatl Assoc Support Care Cancer [Internet]. 2019;1\u201355. Available from: https:\/\/www.mascc.org\/antiemetic-guidelines."},{"key":"bibr11-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs335"},{"key":"bibr12-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1177\/1758834016654902"},{"key":"bibr13-10781552231194077","volume":"109","author":"Zhang Y","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"bibr14-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3304-1"},{"key":"bibr15-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00457"},{"key":"bibr16-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu101"},{"key":"bibr17-10781552231194077","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0187"},{"key":"bibr18-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04257-7"},{"key":"bibr19-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03831-4"},{"key":"bibr20-10781552231194077","volume-title":"Akynzeo\u00ae (netupitant and palonosetron) [prescribing information]","year":"2022"},{"key":"bibr21-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-4640-8"},{"key":"bibr22-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"bibr23-10781552231194077","unstructured":"MASCC. MASCC Antiemesis Tool (MAT); Available from: http:\/\/www.mascc.org\/mat. 2015."},{"key":"bibr24-10781552231194077","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.260"},{"key":"bibr25-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1338"},{"key":"bibr26-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515442"},{"key":"bibr27-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706547"},{"key":"bibr28-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6382"},{"key":"bibr29-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-9-1143"},{"key":"bibr30-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03868-5"},{"key":"bibr31-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.142"},{"key":"bibr32-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0371-5"},{"key":"bibr33-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02786-3"},{"key":"bibr34-10781552231194077","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.10.009"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231194077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231194077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231194077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:57Z","timestamp":1777688937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231194077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/10781552231194077"],"URL":"https:\/\/doi.org\/10.1177\/10781552231194077","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}